Auditory cues assist patients with Parkinson’s disease (on and off L-dopa) during obstacle crossing by Rinaldi, Natalia Madalena et al.
 Rev Bras Educ Fís Esporte, (São Paulo) 2019 Jul-Set; 33(3):333-43 • 333
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Introduction
Auditory cues assist patients with Parkinson’s disease (on and off 
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The positive effects of auditory cues (AC) and 
medication on gait have been independently 
tested in patients with Parkinson’s disease (PD) by 
several investigators1-4. Studies with AC observed 
improvements on some free gait parameters, 
such as cadence and stride length5, as well as on 
more complex tasks, such as turning around and 
double tasks requiring high levels of attention6-8. 
However, the combined effect of AC and drug 
therapy on complex tasks such as obstacle crossing 
has not been investigated in patients with PD. 
PD has been shown to affect locomotor behavior 
during the obstacle crossing task, both during 
the approach and crossing phases, in patients 
tested on medication9,10. In a study investigating 
whether PD affects locomotor behavior as well 
as dynamic stability during obstacle crossing, 
Stegemoller and colleagues11 observed increased 
single (trailing) limb support time and a decrease 
in anteroposterior range of motion, also in 
patients on medication. These findings indicate 
that patients with PD strategically alter locomotor 
behavior in order to decrease mechanical demands 
and increase dynamic stability during obstacle 
crossing tasks.
It is well known that levodopa (L-dopa) improves 
stride length, velocity and muscular strength for 
free gait12-14. In addition, studying patients with 
PD before and after L-dopa, PIERUCCINI-FARIA, 
et al.15 showed that dopaminergic system may 
Abstract
People with Parkinson’s disease (PD) have an impaired locomotor pattern. As a result, the capacity 
of walking independently and the interaction with the environment can be impairment. Uneven 
environments can challenge even more the motor control of these patients to perform the locomotor 
tasks successfully. Besides of the levodopa therapy, the auditory cues have also been utilized to improve 
the gait parameters. However, the effects of auditory cues in gait during obstacle avoidance and the 
association with the levodopa effects are not known. The aim of this study was to investigate the effects 
of AC during obstacle crossing in people with PD (on and off L-dopa) and in healthy control participants. 
A total of 30 individuals participated in the study, including 15 PD patients who were tested both on 
and off L-dopa and 15 healthy adult controls. The task consisted of stepping over an obstacle located 
in the middle of the path under two conditions, i.e., cued and non-cued. We used kinematic, kinetic and 
electromyographic analyses to evaluate individuals' locomotor patterns. Groups differed signifi cantly 
from each other for all analyses and PD patients differed signifi cantly from all other groups when off 
L-dopa. ACs improved the motor control mechanisms used for obstacle crossing in people with PD. These 
results support the notion that external AC therapy may be used as a complement to drug therapy to 
help improve locomotion in PD patients, even on complex tasks such as obstacle crossing.
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be involved in anticipatory temporal but not 
spatial step adjustments when approaching an 
obstacle. Also, spatial regulation during obstacle 
crossing was not significantly modulated by 
dopaminergic replacement therapy, although the 
trail limb vertical foot clearance was shorter during 
off medication when compared with healthy 
control15. We have shown that auditory cues have 
a positive effect in walking pattern of patients with 
PD4, but the effects of auditory cues in PD during 
obstacle crossing is not known. Furthermore, the 
effects of associating L-dopa treatment with AC 
have not been investigated for obstacle crossing to 
date, and some questions emerge: would AC also 
help patients with PD cross obstacles more safely? 
Furthermore, would patients with PD using AC 
adopt the same locomotor patterns observed in 
healthy age-matched controls? Finally, how would 
the combination of L-dopa and AC affect patient 
gait on uneven surfaces? We expected that patients 
with PD have a worse performance than healthy 
older adults during obstacle crossing. We expected 
that this effect would be evidenced for patients 
with PD in off state medication. However, we 
expected that AC could bring positive changes 
in locomotor pattern of patients with PD during 
obstacle crossing in on and o   state medication. 
Moreover, we expected that patients with PD in o   
state in AC condition could have a similar pattern 
of PD in on state even in irregular terrain, such 
as, obstacle avoidance.
Thus, the aim of this study was to assess the 
effects of combining AC and L-dopa on gait in 
patients with PD and compare their performance 
with that of healthy age-matched controls during 
obstacle crossing with and without AC.
This study was conducted according to the 
Declaration of Helsinki. This study was approved 
by the UNESP-RC ethics committee (Protocol 
# 2635) and all participants signed an informed 
consent form.
30 individuals, 15 patients with PD (69.27 ± 
5.75 years old, 8 men and 7 women) tested on 
and off medication and 15 healthy older control 
participants (70.3 ± 6.03 years old, 8 men and 7 
women) participated in this study. These individuals 
also participated in the study of RINALDI, et al.4. 
Patients were diagnosed by a neurologist as having 
stage 1-3 PD on the Hoehn & Yahr (HY) Scale16 
and were undergoing regular treatment with 
levodopa. Control participants did not present any 
neurological diseases and were matched to patients 
on age, gender, and height and body weight. Both 
patients and controls presented independent gait 
without using a cane or walker, preserved cognitive 
functions (necessary for task comprehension), no 
symptoms of depression, no auditory or vestibular 
impairments, and no osteomuscular diseases 
that could interfere with task performance. The 
inclusion criteria for patients with PD were: 1) HY 
stage I to III; 2) regular treatment with levodopa. 
In addition, the exclusion criteria for both groups 
(PD and healthy older control) were: 1) the presence 
of dementia (score < 24 on Mini Mental State 
Examination), 2) the presence of other neurological 
or musculoskeletal disorders.
We initially conducted stride frequency tests to 
obtain baseline values for each participant. These 
variables were used to determine the frequency of 
the auditory cues, which were personalized and 
set 10% higher than each participant’s preferred 
frequency, as described by WILLEMS, et al.17. In trials 
with auditory cues, participants were instructed to 
synchronize when their foot came in contact with 
the ground to the beat of the metronome.
Patients with PD data were collected in the 
morning at two-time points, 1) while patients 
were o!  medication for 12 hours (PD o  ) – and 2) 
one hour after taking L-dopa (PD on). Kinematic 
data were recorded for the right side of the body 
for each participant. Two infrared markers from 
the OPTOTRAK Cetrus motion capture system 
(Northern Digital Inc., Canada) were positioned on 
the " fth metatarsal and lateral facet of the calcaneus 
of each participant’s right lower limb and another 
two were positioned on the " rst metatarsal and on 
the medial facet of the calcaneus on the left.
For electromyographic analysis, bipolar passive 
surface electrodes were positioned on the following 
muscles: tibialis anterior (TA), gastrocnemius 
medialis (GM) and lateralis (GL), vastus lateralis 
(VL) and medialis (VM) and biceps femoris (BF) 
in the right lower limb. Electrodes were placed on 
each muscle surface in the direction of the muscle 
Method
 Rev Bras Educ Fís Esporte, (São Paulo) 2019 Jul-Set; 33(3):333-43 • 335
Parkinson’s disease and obstacle crossing
fibers, according to recommendations made by the 
SENIAM (surface EMG for a non-invasive assessment 
of muscle) project18. In addition, a reference 
electrode was placed on the ulnar styloid process. 
Electromyographic signals were amplified through a 
biological signal conditioner (EMG System do Brasil 
Ltda.), with a gain of 1000, and collected with a 
sampling frequency of 2000 Hz (20 times in the 
pre-amplifier and 100 times in the hardware). Data 
were transformed using an A/D board with an input 
range of +7 to -7 volts and a resolution of 12 bits.
Participants were asked to walk and cross the 
obstacle that was transversally positioned between 
two force plates in the middle of their path. Obstacle 
height was set to half of knee height and participants 
were asked to cross it with the right lower limb 
(leading limb). Each experimental condition (cued: 
with AC and non-cued: without AC) consisted of 
three trials. Therefore, healthy controls performed 
a total of six trials and PD patients performed 12 
trials (6 on and 6 off L-dopa). Trial presentation 
was randomized.
A motion capture system (OPTOTRAK Certus) 
was positioned sagittally to allow all markers to be 
visualized and to obtain three-dimensional records 
of marker displacement with a collection frequency 
of 100 Hz. Two 50 cm x 50 cm force plates 
(AccuGait, Advanced Mechanical Technologies, 
Boston, MA, USA) were embedded approximately 
in the middle of the pathway and covered with 
a black rubber carpet in order to record ground 
reaction force during task execution at a frequency 
of 200 Hz. We used the AMTI NetForce software 
to collect digital data from the plates. EMG signals 
were recorded using the EMG System do Brasil 
software (Brazil), which was used to convert analog 
data into digital data. All data collection systems 
(force platforms, OPTOTRAK and EMG) were 
electronically synchronized. For the auditory cue, 
we used the Metronome Plus software to create 
metronome beats.
Kinematic data were filtered through a second-
order Butterworth filter with a cutoff frequency of 
6Hz. In order to determine the cycle to be analyzed, 
we used the horizontal velocity of the calcaneus 
(calcaneus touching the ground) and the vertical 
velocity of the first/fifth metatarsal (foot being lifted 
from the ground).
Kinetic variables were filtered o! -line through 
a fourth-order Butterworth filter with a cutoff 
frequency of 4 Hz. At the beginning of each period 
of data collection, individuals were weighed on both 
force platforms in an upright position with their 
arms hanging along the sides of the body. Theses 
body mass (BM) values were used to normalize all 
kinetic variables.
Electromyographic data were treated o"  ine in 
two different ways: i) for RMS score collection, 
data were high-pass filtered at 20 Hz and low-pass 
filtered at 500 Hz, and were later rectified; ii) for 
linear envelope acquisition (iEMG), after being 
rectified, data were filtered through a fourth-order 
Butterworth filter at a cutoff frequency of 10 Hz.
All frequencies used for data processing were 
chosen based on the best results obtained with the 
residue analysis. The following kinematic variables 
were analyzed for one complete stride performed 
before reaching the obstacle: length, duration, 
velocity, width, duration of double support, leading 
and trailing foot placement in front of the obstacle, 
and leading and trailing toe clearance. For foot 
placement after crossing the obstacle, we measured 
leading and trailing foot placement. The kinetic 
data were normalized by body weight and used 
to calculate the braking and propulsive impulses 
in two directions: vertical and anterior-posterior. 
These variables were calculated for the leading limb 
(force plate 1) and for the trailing limb (force plate 
2). The electromyographic variables were calculated 
only for the right lower limb (lead foot) in three 
phases: before crossing, during crossing and after 
crossing the obstacle, for the following muscles: 
tibialis anterior (TA), gastrocnemius medialis 
(GM) and lateralis (GL), vastus lateralis (VL) and 
medialis (VM), and biceps femoris (BF). These 
phases were determined following SCHMITZ, et al.19, 
and for each phase, a linear envelope was computed 
to assess the level of muscular activation of each 
analyzed muscle.
For each analysis (kinematic, kinetic and EMG), 
we used a Mann-Whitney and a Wilcoxon posthoc 
test to assess differences among groups (control, 
PD o! , PD on) and conditions (cued and non-
cued). Next, to test for possible L-dopa and/or AC 
effects on patient gait, we conducted a Friedman’s 
repeated measures analysis of variance. Whenever 
needed, we also conducted Bonferroni posthoc 
analyses. Significance was set at 0.05. Moreover, we 
calculated the effect size by the z value as suggested 
by COHEN20. The effect size was calculated by the 
equation (η2 = Z/N). A large effect is 0.6 ≤ η2 < 
0.8, a medium effect is 0.3 ≤ η2 < 0.5 and a small 
effect is 0.0 ≤ η2 < 0.2. These values are presented 
in TABLES 1, 2 and 3.
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Results
Kinematic analysis
Patients with PD (off L-dopa) versus Controls
Mann Whitney test revealed significant 
di erences between the control and PD o  groups 
in the non-cued condition: patients with PD 
presented relatively shorter stride length (U=31, 
p=0.02) and velocity (U=39, p=0.007) and a 
trailing foot placement after crossing the obstacle 
(U=38, p=0.006), as well as greater stride width 
(U=45, p=0.015) and cadence (U=45.5, p=0.005), 
and greater duration of double support (U=37.5, 
p=0.05). For the cued condition, patients with 
PD o   presented relatively slower stride velocity 
(U=54, p=0.001), longer duration of double 
support (U=62.5, p=0.03) and a greater trailing 
foot placement after crossing the obstacle (U=63, 
p=0.04). When conditions (cued vs. non-cued) 
were compared within each group, the Wilcoxon 
test revealed a signi! cant di erence for trailing toe 
clearance for the patients with PD o  group (Z=-
1.97, p=0.04): in the cued condition, patients with 
PD o  presented greater toe clearance. " is result 
indicates a strategic alteration in the locomotor 
pattern of patients with PD o  with the auditory 
cue, even in more challenging tasks, such as crossing 
obstacles. " erefore, for patients with PD o , the 
cued condition improved some of the measured 
parameters, but they still performed worse than 
controls overall.  
Patients with PD (on L-dopa) versus Controls
The Mann Whitney test revealed significant 
differences between the control and PD on groups 
in the non-cued condition: patients with PD on 
presented greater stride width (U=44.5, p=0.008) 
and duration of double support (U=48.5, p=0.013). 
On the other hand, for the cued condition, patients 
had a relatively greater stride cadence, according to 
the Mann Whitney (U=59, p=0.004) and Wilcoxon 
(Z=-3.29, p=0.001) tests, and greater stride duration 
and leading toe clearance (Wilcoxon: Z=-2.55, 
p=0.011 and Z=-2.87, p=0.004, respectively). 
Friedman’s and Wilcoxon posthoc tests revealed 
an increase in stride length and velocity after 
medication in the non-cued condition and an 
increase in cadence and duration of double 
support after medication in the cued condition. 
Interestingly, patients with PD off in the cued 
condition presented shorter duration of double 
support than patients with PD on in the non-cued 
condition. Thus, auditory cues had a stronger effect 
than medication on the duration of double support. 
TABLE 1 presents the kinematic data for patients 
with PD o /on and controls in the cued and non-
cued conditions.
Healthy (Control) PDOFF PDON η2
Kinematic Variables noncued cued noncued cued noncued cued
Stride Length(cm) 114.1(16.1) 119.1(11.5) 90.3(28.9) 99.4(26.9) 102.1(25.6) 108.8(27.5) 0.32
Stride Width (cm) 18.6(6.7) 15.9(4.6) 22.9(8.7) 21.6(8.5) 23.7(9.2) 23.5(9.4) 0.11
Cadence (steps/s) 113.9(14.3) 119.9(15.8) 111.1(13.6) 116.7(21.2) 107.7(11.7) 113.5(10.9) 0.25
Velocity (cm/s) 112.8(19.2) 113.2(18.2) 85.7(26.2) 91.2(26.8) 95.9(24.3) 96.6(25.3) 0.20
Stride Duration (s) 1.07(0.1) 1.01(0.2) 1.08(0.1) 1.01(0.1) 1.13(0.1) 1.07(0.1) 0.15
Double Support Time 
(s)
0.17(0.02) 0.15(0.03) 0.25(0.02) 0.22(0.03) 0.16(0.07) 0.19(0.01) 0.25
Leading foot place-
ment after crossing the 
obstacle (cm)
77(15) 70(16.5) 60.7(12.6) 59.09(11.9) 65.6(15) 64.7(13) 0.34
Leading toe clearance 
(cm)
11.6(0.6) 12.08(0.8) 12.10(1) 12.34(1.07) 12.04(1.07) 11.97(1.16) 0.10
Trailing toe clearance 
(cm)
13.46(0.6) 13.81(0.6) 13.62(0.6) 13.6(0.7) 13.59(1.29) 13.49(0.9) 0.14
TABLE 1 - Mean, standard deviation and effect size (η2) of kinematic variables in noncued and cued conditions 
for control and patients with PD in off (PDOFF) and on (PDON) medication.
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Force Plate 1- before obstacle crossing (leading 
limb)
Patients with PD (o  L-dopa) versus Controls
 e Mann Whitney test indicated that patients 
had a relatively lower braking impulse (anterior-
posterior direction) (U=28, p=0.001) than controls in 
the non-cued condition.  e Wilcoxon test revealed 
an increase in braking impulse (anterior-posterior 
direction) (Z=-2.76, p=0.006), propulsive impulse 
(anterior-posterior direction) (Z=-2.97, p=0.003), 
braking impulse (vertical direction) (Z=-2.98, 
p=0.01), and propulsive impulse (vertical direction) 
(Z=-2.06, p=0.03) for patients with PD o  only in 
the cued condition (TABLE 2). 
Patients with PD (on L-dopa) versus Controls
The Mann Whitney test did not indicate 
differences between PD patients (on L-dopa) and 
controls. The Wilcoxon test revealed that patients 
with PD on had an increase in braking impulse 
(anterior-posterior direction: Z=-2.98, p=0.003; 
vertical: Z=-2.74, p=0.006) and propulsive 
impulse (anterior-posterior direction) (Z=-2.35, 
p=0.019) in the cued condition only (TABLE 2). 
Friedman’s and Wilcoxon post hoc tests revealed 
an increase in braking impulse (anterior-posterior 
direction) after medication in the non-cued 
condition (X2(2)=16.30, p=0.001), confirming 
previous findings that L-dopa alone improves 
certain locomotor parameters. Moreover, patients 
with PD o  presented a lower braking impulse in 
the cued condition than did some patients with PD 
on in the non-cued condition, suggesting that for 
this variable, the auditory cue does not provide an 
advantage over medication (TABLE 2).
Force Plate 2 - after obstacle crossing (trailing 
limb)
The Mann Whitney test revealed that patients 
with PD off presented significantly higher 
propulsive impulse (vertical direction) than 
controls in the cued condition (U=28, p=0.02), 
while the Wilcoxon test showed that patients with 
PD on presented a significantly higher braking 
impulse (anterior-posterior) in the cued condition 
relative to their own performance in the non-cued 
condition (Z=-1.88, p=0.04) (TABLE 2). 
TABLE 2 - Mean, standard deviation and e! ect size ("2) of kinetic variables in noncued and cued conditions 
for control and Parkinson’s disease patients in o!  (PDOFF) and on (PDON) medication.
Kinetic Variables Healthy PDOFF PDON η2












40.31(7.57) 46.29(8.26) 41.75(13.78) 44.38(15.04) 44.2(5.84) 49.42(6.65) 0.50
Braking vertical 
impulse (Bw.s)
28.79(6.36) 34.03(7.61) 34.5(14.78) 37.08(12.59) 32.53(9.03) 36.12(9.07) 0.20












32.14(5.08) 39.65(10.63) 34.08(13.36) 39.52(12.53) 39.01(7.13) 34.92(7.86) 0.10
Braking vertical 
impulse (Bw.s)
34.96(14.38) 45.74(19.19) 48.66(18.36) 51.95(18.71) 47.33(13.98) 47.51(15.23) 0.13
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Electromyographic Analysis
 e Wilcoxon test revealed di erences between 
conditions (cued vs. non-cued) for both groups in 
terms of certain muscle groups.
PD o  versus Controls
Overall, patients with PD o  presented lower 
muscle activity than controls for the following 
muscles in the non-cued condition: VL (before 
obstacle crossing) (Z=-1.91, p=0.05), VM (before 
obstacle crossing) (Z=-2.10, p=0.03), TA (during 
obstacle crossing) (Z=-1.99, p=0.04), TA (after 
obstacle crossing) (Z=-1.91, p=0.05), and VM 
(after obstacle crossing) (Z=-2.16, p=0.03). In the 
cued condition, patients with PD o  displayed an 
increase in the activation of VL muscles (before 
obstacle crossing), VM muscles (before obstacle 
crossing), TA muscles (after obstacle crossing) and 
a decrease in activation of TA muscles (during 
obstacle crossing) and VM muscles (after obstacle 
crossing) relative to their own performance in the 
non-cued condition (TABLE 3).
PD on versus Controls
 e patients with PD on presented signi! cantly 
lower activation of BF muscles (U=50, p=0.016) 
and VM muscles (U=54, p=0.026) than controls 
after obstacle crossing only in the non-cued 
condition. Also, Wilcoxon tests indicated greater 
activity for BF muscles in patients with PD on in 
the cued versus the non-cued condition (Z=-2.98, 
p=0.003) (TABLE 3). 
 e Friedman’s test revealed that in the non-
cued condition, patients with PD on presented 
signi! cantly lower activation of the BF (X2(2)=10.19, 
p=0.0017) and GM muscles (X2(2)=16.95, 
p=0.001) during obstacle crossing. In the non-cued 
condition, patients with PD had lower BF and GM 
activity after medication intake (TABLE 3).
Healthy PDOFF PDON η2























































































VL 28.32 (11.12) 29.12 (11.89) 28.05 (13.78) 30.28 (11.27) 25.23 (9.85) 16.89 (8.05) 0.10
BF 22.58 (13.72) 23.11 (7.27) 29.54 (13.84) 21.17 (9.50) 18.10 (8.26) 18.93 (9.46) 0.11
GL 73.21 (34.31) 82.71 (42.11) 61.21 (22.84) 57.09 (22.16) 70.89 (34.18) 64.53 (24.25) 0.12




89.55 (45.93) 99.27 (33.87) 84.33 (43.05) 54.29 (12.24) 45.78 (18.38) 0.10
















TABLE 3 - Mean, standard deviation and e ect size (#2) of emg variables in noncued and cued conditions 
for control and Parkinson’s disease patients in o  (PDOFF) and on (PDON) medication.
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In the present study, we investigated the e ects of 
auditory cues on gait in patients with PD (on and 
o  L-Dopa) and age-matched control participants 
during obstacle crossing. Overall, we found that 
L-Dopa o  patients performed worse than controls 
and patients with PD on for most variables tested. ! e 
cue condition improved the pattern of locomotion 
during obstacle crossing for patients with PD 
(both o  and on L-Dopa). For some variables, the 
auditory cue had a stronger e ect than medication 
in improving locomotion.
We observed that AC caused patients with PD 
and healthy controls to alter their locomotor patterns 
during obstacle crossing. Rhythmic stimulation 
helped both groups cross obstacles safely by increasing 
the safety margin and muscular activation. In the 
cued condition, the performance of patients with PD 
on was not significantly different than that of healthy 
controls, suggesting that the combined therapeutic 
approach can confer benefits beyond those observed 
with either treatment alone. As expected and shown 
by previous authors, patients with PD on presented 
an improved locomotor pattern compared to when 
they were in o  state. However, with AC, patients 
with PD off had better locomotor control than 
some patients with PD on without AC. ! erefore, 
we conclude that AC may be better than L-dopa 
for gait parameters in some patients with PD, but 
further studies are needed to support these " ndings. 
Also, AC improved the safety margin for the leading 
limb and propulsive braking impulses. This is an 
important result, because with rhythmic auditory 
cues, patients were able to raise their leg by increasing 
Discussion
Healthy PDOFF PDON η2








































































propulsion. Patients with PD on presented similar 
kinematic, kinetic and electromyographic scores as 
controls during the approach and crossing phases. 
These results suggest that ACs improve sensorial 
processing used to perform increasingly challenging 
motor actions. Based on these results, additional 
sensorial and attentional resources must be targeted 
in rehabilitation programs to increase the effect of AC 
on the locomotor pattern of patients with PD, mainly 
during complex tasks, such as crossing obstacles.
! e healthy central nervous system uses visual 
information to track an obstacle in the environment 
and process its characteristics (e.g., height and width) 
in order to make motor adjustments in the lower 
limb to safely and successfully avoid the obstacle21. 
Patients with PD o  medication are usually slower 
at processing this information22 and may also have 
an impaired visual system23, which is why they need 
more time to explore obstacles and remain in double 
support for a longer period of time. However, with 
medication and AC, patients with PD did not need 
more time to process obstacle features, as veri" ed by 
a decrease in stride duration and double support. 
! ese results indicate that a combination of sensorial 
information and drugs is e ective in improving 
gait stability when patients must accomplish more 
complex tasks. L-dopa increases dopamine levels in 
the basal ganglia24, which improves motor symptoms, 
while ACs reach the supplementary motor area 
through the cortex, providing cues to guide the 
movement1. Auditory cues increased the safety 
margin for the leading limb, which, as previously 
explained, helps patients increase their propulsive 
TABLE 3 - (continued)
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impulse while reducing the risk of tripping or falling. 
After avoiding the obstacle, the ACs helps patients 
increase their braking impulse following a disturbing 
situation. We also observed an increase in BF muscle 
activation after obstacle crossing, which indicates 
better stability and foot positioning on the floor 
and a better ability to maintain synchronization 
with the AC.
During the approach phase to the obstacle in the 
non-cued condition, patients with PD (off and on 
L-dopa) presented decreased stride length, cadence 
and velocity and increased stride width and double 
support relative to controls, which indicates postural 
instability, hypometry and hypokinesia, and is in line 
with findings by VITORIO, et al9. We also observed 
weaker force for patients relative to controls before 
obstacle crossing, which reflects the reduced motor 
planning and force (accompanied by muscular 
rigidity) commonly observed in PD. After crossing 
the obstacle, patients with PD also positioned their 
support limb closer to the obstacle, which reflects the 
expected reduced force and stability. These results 
corroborate with those of VAN HEDEL, WALDVOLGEL 
and DIETZ25, which verified that patients with PD 
performed worse on obstacle crossing than healthy 
controls. However, during the cued condition, those 
differences decreased and patients with PD (off 
and on L-dopa) presented similar performance to 
healthy controls on stride width, length and force 
generation peaks. Again, AC may help patients with 
PD strategically adjust locomotor patterns, even in 
more complex situations.
When patients were on L-dopa (PD on), they still 
differed significantly from controls, and some of these 
differences were reduced during the cued condition. 
GALNA, MURPHY and MORRIS10 investigated the 
locomotor pattern of patients with PD on and healthy 
controls during obstacle crossing and found that 
patients approached the obstacle more slowly and 
presented higher double support, indicating higher 
postural instability. While patients scored similarly to 
controls on safety margin and foot placement in front 
of the obstacle (as seen in our own study), they scored 
differently on foot placement after obstacle crossing, 
for example, they placed their lead foot closer to the 
obstacle after crossing. While processing sensorial 
information and motor planning for obstacle crossing 
in the GALNA, MURPHY and MORRIS10 study appeared 
similar between groups, patients with PD presented 
decreased muscular activation of VL and BF during 
the swing phase (crossing) and propulsion, which 
likely indicates reduced recruitment of muscular 
fibers when performing a more challenging task. 
Although patients in the current study were tested 
during the beginning or moderate stages of patients 
with PD, we still observed alterations in CNS-
mediated commands; perhaps at more advanced 
stages of PD, differences in task planning (foot 
placement in front of the obstacle) may become 
more evident.
In sum, L-dopa reduced certain PD symptoms 
such as hypokinesia and bradykinesia, in line with 
other studies that investigated gait in patients with 
PD22,15 and consistent with the observed decreased 
muscular activation of BF and GM, which facilitate 
motor adjustments before obstacle crossing. However, 
the increased knee flexor activation was not enough 
to increase safety margins. In the more challenging 
uneven surface obstacle crossing task presented in 
our study, medication together with AC were not 
enough to increase safety margins, leaving patients 
more vulnerable to falling. In the cued condition, 
patients with PD on showed a decrease in double 
support, indicating improved postural stability 
before obstacle crossing. Interestingly, patients with 
PD o   had higher double support scores in the cued 
condition than patients with PD on in the non-cued 
condition, which reveals that AC may be better than 
levodopa for postural stability, which is essential for 
successful movement. Also, patients did not differ 
significantly on muscular activation scores before and 
after taking medication, which suggests that ACs act 
as an important sensory reinforcement to modulate 
motor responses in these patients.
With the aid of AC, patients improved on some 
parameters (relative to the non-cued condition), even 
in the more challenging situation presented in this 
study (i.e., obstacle crossing on an uneven surface). 
Moreover, auditory cue could not act as a dual task, 
because people with PD have to divide the attention 
between crossing obstacle and synchronize the heel 
contact with the metronome. However, NANHOE-
MAHABIER, et al.26 also showed that patients with 
PD can benefit from auditory cue even in obstacle 
avoidance (complex task) and metronome could not 
be considered as a dual task that negatively affects 
gait. Although changes in locomotor patterns were 
observed among these patients with the aid of the 
rhythmic AC stimulation, this may not be enough 
to make their performance entirely successful. One 
possible solution may be to direct patients’ attention 
to ACs at several points along the path, especially 
during the more challenging tasks, such as obstacle 
crossing. One limitation of this study was that foot 
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placement on the ground was not synchronize with 
auditory cue. Although we found positive effects of 
auditory cue on gait of patients with PD, we could 
not confirm how these patients use this type of cue to 
improve their locomotor performance. Moreover, to 
use this type of cue in some cases could be a complex 
task for patients with PD and it may be considered for 
rehabilitation sections. For example, PLATZ, BROWN 
and MARSDEN27 did not find any effect of auditory cue 
on gait of patients with PD that shows that cues could 
interfere the kinematics aspects of the movement.
Future studies should monitor foot placement 
synchronization in order to determine the exact 
moments at which patients with PD need additional 
assistance. Synchronization may also help elucidate 
whether some changes observed at either the 
approach or crossing phases may reveal that patients 
prioritize the synchronization task at the expense of 
making the proper locomotor adjustments necessary 
for obstacle crossing. Finally, displacement analyses 
in the mediolateral and anteroposterior directions 
would show strategies adopted by patients with PD to 
cross obstacles, and whether these strategies negatively 
affect postural stability.
We conclude that AC may be better than L-dopa 
for some gait parameters in uneven terrain for 
patients with PD, but further studies are needed 
to support these findings. Our results suggest that 
L-dopa combined with AC treatment may be an 
effective way of improving performance in patients 
with PD. Finally, future studies should target 
additional sensorial and attentional resources to 
increase the effect of AC on the locomotor pattern 
of patients with PD.
Resumo
Dica auditiva pode auxilar pacientes com doença de Parkinson (com e sem levodopa) durante a ultrapas-
sagem de obstáculo 
Pessoas com doença de Parkinson (DP) apresentam um padrão locomotor alterado. Como resultado, a 
capacidade de andar independente e a interação com o ambiente pode fi car comprometida. Ambientes 
irregulares podem desafi ar ainda mais o controle motor destes pacientes para realizar a tarefa locomotora 
com sucesso. Além da terapia com levodopa, a dica auditiva tem sido utilizada para melhorar os parâme-
tros locomotores. Entretanto, o efeito da dica auditiva na marcha durante a ultrapassagem de obstáculos 
e a associação com a levodopa não são conhecidos. O objetivo deste estudo foi investigar o efeito da dica 
auditiva durante a ultrapassagem de obstáculos em pessoas com doença de Parkinson (com e sem levodopa) 
e idosos sadios. 30 indivíduos participaram deste estudo, 15 pacientes com DP e 15 idosos sadios. A tarefa 
foi ultrapassar um obstáculo localizado no meio da passarela em duas condições, com e sem dica auditiva. 
As análises cinemática, cinética e eletromiográfi ca foram utilizadas para analisar o padrão locomotor. 
Os grupos foram diferentes, quando os pacientes com DP estavam sem efeito da levodopa. Dica auditiva 
melhorou os mecanismos de controle motor durante a ultrapassagem de obstáculos em pacientes com 
DP. Estes resultados suportam a utilização de dicas sensoriais externas como um complemento à terapia 
medicamentosa para melhorar o padrão locomotor em pacientes com DP mesmo em tarefas complexas, 
como por exemplo, ultrapassar um obstáculo. 
PALAVRAS-CHAVE: Doença de Parkinson; Dica Auditiva; Marcha; Locomoção Adaptativa.
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